Visualize HL7 Example and Test Instances (vi7eti), pronounced /viːˈsɛtiː/
Disclaimer: FOR TEST AND EXAMPLE PURPOSES ONLY! These web pages are not intended to be used as a source of information on medicines. The web pages are not kept up to date and are for demonstration purposes only. For up-to-date information on a medicine, please consult www.ema.europa.eu/medicines or the package leaflet of your medicine.
BACK TO LIST

Laboratory Report

Patient
Name: Nilsson, , Khalid,
DOB: 10-APR-1952 (Age: 73)
Gender: male
Address:
Gengränd 482
691 31 Karlskoga (Sweden)
ID: 8339-594203-6 (ECI)
Report
Date: 16-AUG-2016
Laboratory
dr Ample, Ex
Laboratoire Central Européenne
Boulevard du Jardin Botanique 32
1000 Brussels (Belgium)
Requested by
Karlskoga Lasarett
691 31 Karlskoga (Sweden)
Specimen
Collected: 15-AUG-2016

Chemistry

Test 16-AUG-2016 Reference Range Unit
Hemoglobin A1c/Hemoglobin.total in Blood 6.2 4.5 - 6.4 %
Glucose [Mass/volume] in Blood 71.0 70 - 99 mg/dL
Urea nitrogen [Mass/volume] in Blood 12.6 7 - 20 mg/dL
Creatinine [Mass/volume] in Blood 0.9 0.9 - 1.3 mg/dL
Calcium [Mass/volume] in Blood 8.5 L 8.6 - 10.2 mg/dL
Sodium [Moles/volume] in Blood 142.9 135 - 145 mmol/L
Potassium [Moles/volume] in Blood 3.9 3.5 - 5.1 mmol/L
Chloride [Moles/volume] in Blood 101.7 98 - 108 mmol/L
Carbon dioxide, total [Moles/volume] in Blood 25.1 22 - 29 mmol/L
Cholesterol [Mass/volume] in Serum or Plasma 188.3 0 - 200 mg/dL
Triglyceride [Mass/volume] in Serum or Plasma 133.0 40 - 150 mg/dL
Cholesterol in LDL [Mass/volume] in Serum or Plasma by Direct assay 134.7 H 0 - 130 mg/dL
Cholesterol in HDL [Mass/volume] in Serum or Plasma 27.1 L 40 - 100 mg/dL

Annotation

Conclusion and Recommendations based on this report and previous findings known to us
The patient shows mildly decreased calcium and HDL cholesterol, and elevated LDL cholesterol, indicating increased cardiovascular risk. HbA1c is at the upper limit of normal, suggesting prediabetes. Renal function, electrolytes, and other parameters are within normal limits. Recommend addressing dyslipidemia and monitoring glycemic control.